Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cystic fibrosis
Pharma
Vertex's Casgevy launch progresses as CF drugs post solid growth
Vertex's Casgevy launch appears to be outpacing that of its bluebird rival Lyfgenia. Meanwhile, Vertex's cystic fibrosis business continues to soar.
Fraiser Kansteiner
May 7, 2024 11:23am
NICE rejects cost effectiveness of Vertex's cystic fibrosis meds
Nov 6, 2023 2:42pm
'The Top Line': 2022's top M&A deals and 2023's potential
Feb 10, 2023 6:00am
Vertex's Trikafta at center of new pricing controversy
Feb 7, 2023 10:59am
Don't pigeonhole Vertex as a rare disease company, execs say
May 6, 2022 7:55am
Vertex's CEO scored a major pay bump in 2021
Apr 8, 2022 11:10am